Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
1.460
-0.080 (-5.19%)
Dec 5, 2025, 4:00 PM EST - Market closed
Calidi Biotherapeutics Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Calidi Biotherapeutics.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Calidi Biotherapeutics.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $120 | Strong Buy | Initiates | $120 | +8,119.18% | Jun 27, 2024 |
| Baird | Baird | Buy Maintains $540 → $240 | Buy | Maintains | $540 → $240 | +16,338.36% | May 15, 2024 |
| Baird | Baird | Buy Maintains $1,080 → $540 | Buy | Maintains | $1,080 → $540 | +36,886.30% | Mar 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $1,320 → $240 | Strong Buy | Maintains | $1,320 → $240 | +16,338.36% | Mar 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $1,320 | Strong Buy | Initiates | $1,320 | +90,310.96% | Nov 22, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-7.59
from -35.70
EPS Next Year
-5.68
from -7.59
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | n/a | n/a | ||
| Avg | n/a | n/a | ||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -7.81 | -5.85 | |
| Avg | -7.59 | -5.68 | |
| Low | -7.29 | -5.46 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.